Raffi Asadorian is Chief Financial Officer of ACELRX PHARMACEUTICALS INC. Currently has a direct ownership of 37,578 shares of ACRX, which is worth approximately $42,463. The most recent transaction as insider was on Dec 02, 2024, when has been sold 155 shares (Common Stock) at a price of $0.77 per share, resulting in proceeds of $119. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 37.6K
0.41% 3M change
70.18% 12M change
Total Value Held $42,463

RAFFI ASADORIAN Transaction History

Date Transaction Value Shares Traded Shares Held Form
Dec 02 2024
SELL
Open market or private sale
$119 $0.77 p/Share
155 Reduced 0.41%
37,578 Common Stock
Mar 03 2024
SELL
Payment of exercise price or tax liability
$725 $1.3 p/Share
558 Reduced 1.46%
37,733 Common Stock
Feb 14 2024
BUY
Grant, award, or other acquisition
-
18,000 Added 31.98%
38,291 Common Stock
Feb 11 2024
SELL
Payment of exercise price or tax liability
$984 $1.1 p/Share
895 Reduced 4.22%
20,291 Common Stock
Feb 10 2024
SELL
Payment of exercise price or tax liability
$984 $1.1 p/Share
895 Reduced 4.05%
21,186 Common Stock
Mar 03 2023
SELL
Payment of exercise price or tax liability
$668 $1.31 p/Share
510 Reduced 2.26%
22,081 Common Stock
Feb 11 2023
SELL
Payment of exercise price or tax liability
$1,466 $1.68 p/Share
873 Reduced 3.72%
22,591 Common Stock
Feb 10 2023
BUY
Grant, award, or other acquisition
-
5,875 Added 20.02%
23,464 Common Stock
Feb 06 2023
SELL
Payment of exercise price or tax liability
$1,246 $2.02 p/Share
617 Reduced 3.39%
17,589 Common Stock
Mar 03 2022
SELL
Payment of exercise price or tax liability
$3,248 $0.41 p/Share
7,923 Reduced 2.13%
364,205 Common Stock
Feb 11 2022
SELL
Payment of exercise price or tax liability
$3,171 $0.4 p/Share
7,927 Reduced 2.11%
368,080 Common Stock
Feb 11 2022
BUY
Grant, award, or other acquisition
-
117,500 Added 23.81%
376,015 Common Stock
Feb 06 2022
SELL
Payment of exercise price or tax liability
$4,038 $0.43 p/Share
9,391 Reduced 3.51%
258,515 Common Stock
Mar 03 2021
BUY
Grant, award, or other acquisition
-
68,750 Added 20.87%
260,597 Common Stock
Feb 11 2021
SELL
Payment of exercise price or tax liability
$23,733 $2.63 p/Share
9,024 Reduced 4.69%
183,299 Common Stock
Feb 06 2021
SELL
Payment of exercise price or tax liability
$24,382 $2.59 p/Share
9,414 Reduced 4.67%
192,323 Common Stock
RA

Raffi Asadorian

Chief Financial Officer
Redwood City, CA

Track Institutional and Insider Activities on ACRX

Follow ACELRX PHARMACEUTICALS INC and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ACRX shares.

Notify only if

Insider Trading

Get notified when an Acelrx Pharmaceuticals Inc insider buys or sells ACRX shares.

Notify only if

News

Receive news related to ACELRX PHARMACEUTICALS INC

Track Activities on ACRX